Source link : https://www.newshealth.biz/health-news/lillys-zepbound-tops-wegovy-for-weight-loss-in-head-to-head-trial/
(Reuters) -Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk’s Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines. The drugmaker’s shares rose marginally in premarket trading, while Novo Nordisk’s Copenhagen-listed shares slipped about 1%. In the 751-person trial […]
Author : News Health
Publish date : 2024-12-04 11:52:38
Copyright for syndicated content belongs to the linked Source.